Trending Stock News

Curis, Inc. (CRIS) EPS Estimated At $-0.09; Tweedy Browne Company Has Decreased Johnson & Johnson (JNJ) Holding

Tweedy Browne Company Llc decreased Johnson & Johnson (JNJ) stake by 0.28% reported in 2017Q3 SEC filing. Tweedy Browne Company Llc sold 6,465 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The Tweedy Browne Company Llc holds 2.29M shares with $298.06 million value, down from 2.30M last quarter. Johnson & Johnson now has $351.59 billion valuation. The stock decreased 1.71% or $2.28 during the last trading session, reaching $130.87. About 6.56 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since February 21, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.

Analysts expect Curis, Inc. (NASDAQ:CRIS) to report $-0.09 EPS on March, 8.They anticipate $0.01 EPS change or 12.50% from last quarter’s $-0.08 EPS. After having $-0.11 EPS previously, Curis, Inc.’s analysts see -18.18% EPS growth. The stock decreased 0.60% or $0.0033 during the last trading session, reaching $0.5427. About 933,833 shares traded. Curis, Inc. (NASDAQ:CRIS) has risen 2.47% since February 21, 2017 and is uptrending. It has underperformed by 14.23% the S&P500.

Investors sentiment is 0.83 in 2017 Q3. Its the same as in 2017Q2. It has no change, as 45 investors sold JNJ shares while 871 reduced holdings. only 111 funds opened positions while 645 raised stakes. 1.71 billion shares or 0.90% less from 1.73 billion shares in 2017Q2 were reported. Sit Invest Associate owns 485,640 shares or 1.57% of their US portfolio. Windward Co Ca accumulated 91,013 shares. Van Cleef Asset Managementinc holds 78,520 shares or 2.78% of its portfolio. Pekin Singer Strauss Asset Il holds 42,649 shares or 1.04% of its portfolio. First Fin Natl Bank invested in 94,009 shares. Tirschwell Loewy owns 199,183 shares or 3.92% of their US portfolio. Horrell Cap Mgmt has invested 0.04% in Johnson & Johnson (NYSE:JNJ). Palladium Ptnrs Ltd Co owns 1.69% invested in Johnson & Johnson (NYSE:JNJ) for 170,544 shares. Buckingham Capital Mngmt Inc holds 59,174 shares or 1.7% of its portfolio. Monroe Bank And Tru Mi reported 11,336 shares or 0.45% of all its holdings. Halsey Ct reported 1.47% stake. Institute For Wealth Lc invested 0.89% of its portfolio in Johnson & Johnson (NYSE:JNJ). 255,409 are held by Wesbanco Fincl Bank. Financial Bank Pictet & Cie (Asia) reported 4.75% in Johnson & Johnson (NYSE:JNJ). Levin Cap Strategies Ltd Partnership reported 437,240 shares stake.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 5 Sell and 6 Hold. Therefore 52% are positive. Johnson & Johnson had 89 analyst reports since August 7, 2015 according to SRatingsIntel. Barclays Capital upgraded the stock to “Overweight” rating in Tuesday, December 1 report. Jefferies maintained Johnson & Johnson (NYSE:JNJ) rating on Friday, July 14. Jefferies has “Hold” rating and $14500 target. The rating was maintained by Jefferies with “Hold” on Tuesday, March 15. The firm has “Buy” rating given on Monday, July 10 by RBC Capital Markets. S&P Research maintained the stock with “Buy” rating in Wednesday, October 14 report. The firm has “Buy” rating by RBC Capital Markets given on Wednesday, October 18. The firm earned “Buy” rating on Thursday, October 19 by Credit Suisse. The stock of Johnson & Johnson (NYSE:JNJ) has “Hold” rating given on Friday, June 16 by Jefferies. Argus Research maintained the shares of JNJ in report on Wednesday, October 18 with “Buy” rating. On Thursday, January 26 the stock rating was downgraded by Wells Fargo to “Market Perform”.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on April, 17. They expect $2.01 earnings per share, up 9.84% or $0.18 from last year’s $1.83 per share. JNJ’s profit will be $5.40 billion for 16.28 P/E if the $2.01 EPS becomes a reality. After $1.74 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts 15.52% EPS growth.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $88.99 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Leave a Reply

Your email address will not be published. Required fields are marked *